LUMAKRAS vs TECENTRIQ

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 18, 2026·How we rate

Possible drug interaction. LUMAKRAS and TECENTRIQ are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	LUMAKRAS	TECENTRIQ
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	SOTORASIB	ATEZOLIZUMAB
Manufacturer	Amgen Inc	Genentech Inc
Dosage forms	Tablet	Injectable
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma	Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Hepatocellular Carcinoma

lumakras tecentriq

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

SOTORASIB

ATEZOLIZUMAB

Manufacturer

Amgen Inc

Genentech Inc

Dosage forms

Tablet

Injectable

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma

Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Hepatocellular Carcinoma

Frequently asked questions

Which is better-rated, Lumakras or Tecentriq?

By our independent rating, Lumakras scores higher — 3.6 vs 3.5 out of 5 for Tecentriq. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Lumakras and Tecentriq?

Lumakras contains Sotorasib, while Tecentriq contains Atezolizumab — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.